Rubicon Research (RUBICON) Q4 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 25/26 earnings summary
13 Aug, 2026Executive summary
Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, with an unmodified audit opinion from Deloitte Haskins & Sells LLP.
A final dividend of ₹1.50 per equity share was recommended for FY26, subject to shareholder approval at the AGM.
The company completed a successful IPO in October 2025, raising ₹13,775 million, with shares listed on NSE and BSE.
Financial highlights
Consolidated revenue from operations for FY26 was ₹17,539.56 million, up from ₹12,842.72 million in FY25.
Net profit after tax for FY26 was ₹2,467.35 million, compared to ₹1,343.61 million in FY25.
Standalone revenue for FY26 was ₹13,060.82 million, up from ₹10,738.43 million in FY25.
Standalone net profit after tax for FY26 was ₹1,881.65 million, up from ₹1,675.37 million in FY25.
Basic EPS (consolidated) for FY26 was ₹15.52, up from ₹8.82 in FY25.
Outlook and guidance
The company is focused on deploying unutilized IPO proceeds for debt repayment and strategic acquisitions.
A definitive agreement was signed to acquire 85% of Arinna Lifesciences Limited for ₹1,759.17 million, completed in April 2026.
Latest events from Rubicon Research
- Q1 FY27 delivered strong revenue and profit growth, with margin guidance raised to 23%.RUBICON
Q1 26/27 - Quarterly net profit of ₹255.65 million on revenue of ₹3,167.19 million, driven by US sales.RUBICON
Q1 25/26 - Revenue up 50% YoY, net profit at ₹13,436 lakhs, and major US acquisition completed.RUBICON
Q4 24/25 - Strong revenue and profit growth, successful IPO, and strategic biotech investments.RUBICON
Q2 25/26 - Strong revenue and profit growth, successful IPO, and strategic investments marked the quarter.RUBICON
Q3 25/26